Exchange: NYSEArca·Updated 07:30 PM EST

DFAX News

News
all
press releases
BLCO Stock Drops After-Hours — Bausch + Lomb Halts Glaucoma Eye Drop Program After Trial Failure
After 28 days of treatment, BL1107 did not meet its main goal of improving visual field scores in a study.
Stocktwits
BLCO Stock Drops After-Hours — Bausch + Lomb Halts Glaucoma Eye Drop Program After Trial Failure
After 28 days of treatment, BL1107 did not meet its main goal of improving visual field scores in a study.
Stocktwits
More News
Stellantis is looking to bring €190 billion in revenue from 2030, compared to €154 billion reported in 2025.
Stocktwits
Rise in oil prices amid the ongoing conflict in the middle-east has spiked Brent crude and other energy product prices.
Stocktwits
The Ozempic pill will be launched in Q2 2026 and be available in doses 1.5 mg, 4 mg, and 9 mg.
Stocktwits
The drugmaker now expects fiscal 2026 adjusted sales down 5% to 13%.
Stocktwits
Keefe Bruyette downgraded Bitfarms to ‘Market Perform’ from ‘Outperform’.
Stocktwits
Reuters reported on Friday, citing IQVIA data shared by analysts, that Novo’s weight-loss pill was prescribed 18,410 times in the week ended January 16.
Stocktwits
The failed clinical program evaluated rifaximin SSD for the delay of the first episode of hepatic encephalopathy (HE) in adults with liver cirrhosis who experienced no prior episodes.
Stocktwits
Novo and Aspect have been collaborating since 2023 to develop cellular medicines, and said that the new partnership phase builds on the momentum achieved in the existing collaboration.
Stocktwits
Epcoritamab demonstrated an improvement in progression-free survival in certain patients with relapsed or refractory diffuse large B-cell lymphoma, the company said.
Stocktwits

Advertisement|Remove ads.